None of intervention
OtherNone of intervention
NCT Number: NCT05468905
This is a multi-center longitudinal study that consists of five cohorts: cognitive normal aging (CN), Subjective cognitive impairment (SCI), mild cognitive impairment (MCI), Alzheimer's disease (AD) and vascular cognitive impairment (VCI). The goals of this study are as follow: 1.To establish longitudinal cohort study database containing comprehensive epidemiological data, neuropsychological test data, laboratory parameters, image data and biological samples. 2. To determine the risk factors of AD and other dementias. 3. To explore the conversion rates from CN to SCI, MCI or AD and the risk factors as well as biomarkers for the progression from CN to SCI, MCI or AD. 4. To explore and validate blood, CSF, urine, imaging and other biomarkers for the early detection and progression of AD.
Interested in participating?
Request Info40 year–99 year
All sexes
Observational
Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
As the population ages in China, the number of patients with neurocognitive disorders such as Alzheimer's disease (AD) and vascular cognitive impairment (VCI) is steadily increasing. The burden of cognitive impairment in China has been an important public health problem. Cohort study on aging and cognitive impairment is urgent to better understand and address this issue. Early prevention, diagnosis and treatment are critical for reduction the burden of cognitive impairment. In this prospective study, subjects will be recruited into one of the five groups based on inclusion and exclusion criteria: 1) CN, 2) MCI 3) AD and 4) VCI. Each of the subjects will be followed up at designated time points up to 5 years. Epidemiological data, medical, imaging (MRI and PET scans), genetic information and various biological samples will be collected during the baseline and follow-up period.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
Exclusion criteria
Cognitive normal aging (CN)
<!-- -->
<!-- -->
<!-- -->
None of intervention
Time frame: 5 years
All of the participants will be evaluated by cognitive assessment scale annually.
Time frame: 5 years
All of the participants will be evaluated by cognitive assessment scale annually.
Time frame: 5 years
Cerebrospinal fluid, plasma, saliva and urine biomarkers included Aβ42, Aβ40, phosphated tau and total tau, and other novel biomarkers.
Time frame: 5 years
Imaging biomarkers included cerebral atrophy, amyloid and tau deposition of whole brain or hippocampus, glucose metabolism and other novel biomarkers.
Time frame: 5 years
Fecal microbiome will be analyzed by 16S rRNA gene sequencing and metagenome sequencing.
Time frame: 5 years
Gait characteristics such as stride-to-stride variability of stride time, and gait speed were evaluated by 3D gait detection.
Contact information is provided by the study sponsor or research team.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Other
Acronym: CLACIS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05929703
Aging, Alzheimer Disease
Orange, California, United States
View Trial DetailsNCT05372172
Aging, Alzheimer Disease
Nashville, Tennessee, United States
View Trial DetailsNCT03702907
Aging, Aging Disorder
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06366867
Aging, Alzheimer Disease
Edmonton, Canada
View Trial Details